MSN Labs To Launch COVID-19 Drug In India After Licensing Agreement With Eli Lilly

• ByStartupStory     |    May 15, 2021

MSN Labs to launch COVID-19 drug Baricitinib in India; they have entered into a royalty-free, non-exclusive, and voluntary licence agreement with US-based Eli Lilly and Company to manufacture and market Baricitinib by MSN Labs to launch COVID-19 drug in India.

Regarding MSN to launch COVID-19 drug which will be launched under the brand name BARIDOZ in two strengths, 2 mg and 4mg. MSN has developed the active pharmaceutical ingredient and the formulation of Baricitinib in its in-house R&D and manufacturing units. Dr MSN Reddy, CMD, MSN Group, said, “This collaboration with Eli Lilly and Company is a landmark milestone in India’s fight against COVID-19, and will thus help in increasing the availability and affordability of baricitinib”.

As part of the COVID treatment range MSN to launch COVID-19 drug, MSN has already launched FAVILOW (Favipiravir) in the strengths of 200mg, 400mg, & 800mg, and OSELOW (Oseltamivir) as 75 mg capsules.

According to a statement by the company regarding MSN to launch COVID-19 drug, Baricitinib has been granted a restricted emergency use approval in India by the Central Drugs Standard Control Organisation for emergency use in combination with Remdesivir for the treatment of suspected or laboratory confirmed COVID-19 in hospitalised adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

Follow Startup Story